New hope for hard-to-treat lung cancer: triple therapy targets resistant tumors

NCT ID NCT06495125

First seen Apr 07, 2026 · Last updated Apr 28, 2026 · Updated 3 times

Summary

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in 50 adults with advanced LKB1-mutant lung adenocarcinoma that no longer responds to standard anti-PD1 treatment. The goal is to see if this triple therapy can shrink tumors or slow cancer growth. Participants must have a specific genetic mutation (LKB1) and have tried prior treatments without success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory Saint Joseph's Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact Email: •••••@•••••

  • Emory University Hospital Midtown

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Email: •••••@•••••

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.